Prilosec OTC Formulation Targeted In Mylan Labs Suit
This article was originally published in The Tan Sheet
Executive Summary
Mylan Laboratories' lawsuit against Procter & Gamble over the formulation of Prilosec OTC is the most recent in a string of challenges for the over-the-counter heartburn medication
You may also be interested in...
Mylan Seeks Halt Of “Misleading” Prilosec OTC Ad Claims In Suit
Mylan Labs requests preliminary and permanent injunctions against Procter & Gamble ad claims that Prilosec OTC and Rx Prilosec are the same drug in its complaint against the firm in Manhattan federal court
Mylan Says PPI Formulary Impact Unclear As Omeprazole Options Increase
Prescription proton pump inhibitor manufacturers are becoming increasingly wary of the effect Prilosec OTC will have on the formulary status of generic offerings
Prilosec OTC Claims Found False; P&G Appeals Federal Court Ruling
Procter & Gamble says the impact of a Sept. 19 court-ordered preliminary injunction against the use of its "one pill, 24 hours, zero heartburn" claim for Prilosec OTC will be "trivial" and immaterial to the product launch